Format

Send to

Choose Destination
Blood. 2014 Oct 2;124(14):2184-9. doi: 10.1182/blood-2014-05-578286. Epub 2014 Aug 26.

How does lenalidomide target the chronic lymphocytic leukemia microenvironment?

Author information

1
Department of Hematology and Lymphoma and Myeloma Centre Amsterdam (LYMMCARE), Academic Medical Center, Amsterdam, The Netherlands;
2
Department of Internal Medicine III, Salzburg Cancer Research Institute, Paracelsus Medical University Salzburg, Salzburg, Austria; and.
3
Department of Haemato-Oncology, Division of Cancer Studies, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.

Abstract

Immunotherapy has emerged as a viable clinical strategy to harness endogenous antitumor T-cell immunity. Lenalidomide is an oral immunomodulatory drug that repairs antitumor T-cell function and is showing efficacy in ongoing chronic lymphocytic leukemia (CLL) and lymphoma clinical trials. This article focuses on advances in our understanding of its mechanism of action in the tumor microenvironment and provides a clinical update in CLL. Challenges associated with this drug and its potential use in the targeted drug treatment era are discussed.

PMID:
25161268
DOI:
10.1182/blood-2014-05-578286
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center